| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Salvatore Cisternino | Q39592302 |
| Jean-Michel Scherrmann | Q96068174 | ||
| P2093 | author name string | Bruno Saubaméa | |
| Xavier Declèves | |||
| Nicolas Tournier | |||
| P433 | issue | 26 | |
| P921 | main subject | blood–brain barrier | Q221694 |
| opioid | Q427523 | ||
| P304 | page(s) | 2829-2842 | |
| P577 | publication date | 2011-01-01 | |
| P1433 | published in | Current Pharmaceutical Design | Q5195068 |
| P1476 | title | Opioid transport by ATP-binding cassette transporters at the blood-brain barrier: implications for neuropsychopharmacology | |
| P478 | volume | 17 |
| Q53705160 | A Conformationally Gated Model of Methadone and Loperamide Transport by P-Glycoprotein. |
| Q36441533 | ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics |
| Q39181431 | Acute pain Factors predictive of post-operative pain and opioid requirement in multimodal analgesia following knee replacement |
| Q42484273 | Blood-brain and retinal barriers show dissimilar ABC transporter impacts and concealed effect of P-glycoprotein on a novel verapamil influx carrier |
| Q44338807 | Can P-glycoprotein expression on malignant tumor tissues predict opioid transport at the blood-brain barrier in cancer patients? |
| Q38925591 | Carrier-mediated cocaine transport at the blood-brain barrier as a putative mechanism in addiction liability. |
| Q94585924 | Choroid plexus and the blood-cerebrospinal fluid barrier in disease |
| Q36910582 | Coexistence of passive and proton antiporter-mediated processes in nicotine transport at the mouse blood-brain barrier. |
| Q38544082 | Considerations when using pharmacokinetic/pharmacodynamic modeling to determine the effectiveness of simple analgesics in children. |
| Q37297410 | Cyclosporine-inhibitable blood-brain barrier drug transport influences clinical morphine pharmacodynamics |
| Q36036200 | Cyclosporine-inhibitable cerebral drug transport does not influence clinical methadone pharmacodynamics |
| Q48490305 | Discrepancies in the P-glycoprotein-mediated transport of (18)F-MPPF: a pharmacokinetic study in mice and non-human primates. |
| Q97516540 | Effects of Drugs of Abuse on the Blood-Brain Barrier: A Brief Overview |
| Q28482464 | Enhanced brain disposition and effects of Δ9-tetrahydrocannabinol in P-glycoprotein and breast cancer resistance protein knockout mice |
| Q50672428 | Impact of P-glycoprotein at the blood-brain barrier on the uptake of heroin and its main metabolites: behavioral effects and consequences on the transcriptional responses and reinforcing properties. |
| Q28578377 | Induction of P-glycoprotein and Bcrp at the rat blood-brain barrier following a subchronic morphine treatment is mediated through NMDA/COX-2 activation |
| Q38093852 | Metabolic and toxicological considerations of the opioid replacement therapy and analgesic drugs: methadone and buprenorphine |
| Q57812851 | Modulation of Opioid Transport at the Blood-Brain Barrier by Altered ATP-Binding Cassette (ABC) Transporter Expression and Activity |
| Q36942721 | Neurovascular unit in chronic pain |
| Q64936844 | No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Buprenorphine/Naloxone in Healthy Participants and Participants Receiving Stable Opioid Agonist Therapy. |
| Q59356119 | No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Methadone in Participants Receiving Maintenance Opioid Agonist Therapy |
| Q39285381 | Opioids and the blood-brain barrier: a dynamic interaction with consequences on drug disposition in brain. |
| Q38071975 | Personalized treatment of pain |
| Q38061498 | Pharmacogenomics of opioids and perioperative pain management |
| Q38120053 | Spinal opioid bioavailability in postoperative pain |
| Q36591611 | Targeted drug delivery to treat pain and cerebral hypoxia |
| Q28088708 | Targeting transporters: promoting blood-brain barrier repair in response to oxidative stress injury |
| Q37690995 | The balance between effective opioid-based pain management and patient safety: can it be achieved? |
| Q57462903 | Understanding the Agent, Part I: Opioid Biology and Basic Pharmacology |
| Q34686627 | Validated UPLC-MS/MS method for determination of moclobemide in human brain cell supernatant and its application to bidirectional transport study |
| Q51119182 | Why is there no morphine concentration-response curve for acute pain? |
Search more.